title: [Ondansetron: a meta-analysis on its efficacy to prevent postoperative nausea and vomiting after craniotomy in adults and children].
abstract: OBJECTIVE
  To justify the use of ondansetron as a preventive treatment for postoperative nausea and vomiting (PONV) of adults and children in neurosurgery.
  
  
  METHODS
  Meta-analysis.
  
  
  METHODS
  Six published, randomized, double-blinded, placebo-controlled trials were selected to study the efficacy of ondansetron on PONV in adults undergoing craniotomy. Similarly, three studies were selected in children. The treated adults received 4 or 8 mg of ondansetron during the peroperative period. As for children, they were given a repeated dose of 0.15 mg/kg of ondansetron. The emetic episodes noted for 24 hours in children and until 48 hours in adults were analyzed. The results were presented as relative risks (RR) following a fixed model and a 95% confidence interval (CI). The test for heterogeneity was measured with the I(2) Altman DG test.
  
  
  RESULTS
  At 24 hours, among the 308 adults tested, nausea and vomiting were significantly reduced by 22% and 57%, respectively; no significant reduction in vomiting was noted for the 149 children patients. At 48 hours, no significant modification was observed in adults.
  
  
  CONCLUSIONS
  Peroperative intravenous dose of ondansetron 4 mg in neurosurgery in adults is required to prevent PONV during the first postoperative 24 hours. However, further studies are needed to determine best time and dose infusion to prolong clinical efficacy.
authors.affiliation: Département d'anesthésie-réanimation, hôpital neurologique et neurochirurgical Pierre-Wertheimer, 59, boulevard Pinel, 69500 Bron, France.
authors.forename: F
authors.initials: F
authors.lastname: Frost
authors.forename: F
authors.initials: F
authors.lastname: Dailler
authors.forename: F
authors.initials: F
authors.lastname: Duflo
mesh_terms: D000328:Adult; D000367:Age Factors; D018686:Anesthetics, Intravenous / Q000009:adverse effects; D000932:Antiemetics / Q000008:administration & dosage / Q000627:therapeutic use*; D001932:Brain Neoplasms / Q000150:complications / Q000601:surgery; D002648:Child; D003399:Craniotomy; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004828:Epilepsies, Partial / Q000150:complications / Q000601:surgery; D006257:Head / Q000601:surgery; D006801:Humans; D017294:Ondansetron / Q000008:administration & dosage / Q000627:therapeutic use*; D020250:Postoperative Nausea and Vomiting / Q000517:prevention & control*; D011446:Prospective Studies; D016032:Randomized Controlled Trials as Topic / Q000706:statistics & numerical data; D012306:Risk; D013874:Thiopental / Q000009:adverse effects; D013997:Time Factors
chemical_list: D018686:Anesthetics, Intravenous; D000932:Antiemetics; D017294:Ondansetron; D013874:Thiopental